CDK8 and triple-negative breast carcinoma: Vanicoside B is known to be able to exhibit pro-antitumor activity, in particular, to inhibit the two-step skin tumor carcinogenesis in mice induced by 12-O-tetradecanoylphorbol-13-acetate (TPA), and has shown antitumor activity against a panel of cancer cell lines in MDA-MB-231 triple negative breast cancer (TNBC) cells by affecting cyclin-dependent kinase 8 (CDK8) [43].